Acrigen Biosciences is an early-stage biotech company developing technologies to improve the efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. The current challenge is to optimize the gene editing process to eliminates unwanted side effects and unanticipated editing in a patient. Acrigen Biosciences technology is based on a class of proteins, anti-CRISPR or Acr proteins, that precisely deactivate the Cas proteins serving as a gene editing “off switch”. The company is co-founded by Professor Joseph Bondy-Denomy, currently at UCSF, who discovered Acr proteins. Acrigen Biosciences is the first company developing Acr proteins to better control the CRISPR-Cas gene editing process to create an improved CRISPR gene editing platform for safe and effective gene therapies.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2019
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Acrigen Biosciences founded?
Acrigen Biosciences was founded in 2019.
What industry is Acrigen Biosciences in?
Acrigen Biosciences operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Acrigen Biosciences based?
Acrigen Biosciences is headquartered in Berkeley, United States.
Find investors for your startup like Acrigen Biosciences
Gritt sends AI-personalised outreach to each investor — from your Gmail